Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The immunology of type 1 diabetes
KC Herold, T Delong, AL Perdigoto, N Biru… - Nature Reviews …, 2024 - nature.com
Following the seminal discovery of insulin a century ago, treatment of individuals with type 1
diabetes (T1D) has been largely restricted to efforts to monitor and treat metabolic glucose …
diabetes (T1D) has been largely restricted to efforts to monitor and treat metabolic glucose …
T-cell exhaustion in immune-mediated inflammatory diseases: new implications for immunotherapy
Z Gao, Y Feng, J Xu, J Liang - Frontiers in immunology, 2022 - frontiersin.org
Immune-mediated inflammatory diseases (IMIDs) are referred to as highly disabling chronic
diseases affecting different organs and systems. Inappropriate or excessive immune …
diseases affecting different organs and systems. Inappropriate or excessive immune …
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …
function and immune cells among participants in a previously reported randomized …
Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function
OBJECTIVE In November 2022, teplizumab-mzwv became the first drug approved to delay
the onset of stage 3 type 1 diabetes in adults and children age≥ 8 years with stage 2 type 1 …
the onset of stage 3 type 1 diabetes in adults and children age≥ 8 years with stage 2 type 1 …
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and …
Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not
all subjects respond, and the duration of response is limited. Our aim was to determine …
all subjects respond, and the duration of response is limited. Our aim was to determine …
[HTML][HTML] A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and …
Methods Adults (18–42 years) and adolescents (12–17 years) with type 1 diabetes
diagnosed within 150 days were enrolled, with documented evidence of at least one …
diagnosed within 150 days were enrolled, with documented evidence of at least one …
Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression
Although most patients with type 1 diabetes (T1D) retain some functional insulin-producing
islet β cells at the time of diagnosis, the rate of further β cell loss varies across individuals. It …
islet β cells at the time of diagnosis, the rate of further β cell loss varies across individuals. It …
Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Type 1 diabetes is an autoimmune disease characterised by the destruction of insulin
producing beta cells in the pancreas. Whilst it remains unclear what the original triggering …
producing beta cells in the pancreas. Whilst it remains unclear what the original triggering …
Teplizumab: first approval
SJ Keam - Drugs, 2023 - Springer
Teplizumab (teplizumab-mzwv; TZIELD™) is a CD3-directed monoclonal antibody
(humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of type 1 …
(humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of type 1 …